Rakovina Therapeutics Announces Appointment of Dr. David Kideckel as Chief Financial Officer

Core Insights - Rakovina Therapeutics Inc. has appointed Dr. David M. Kideckel as Chief Financial Officer, pending approval from the TSX Venture Exchange [1] - Dr. Kideckel has nearly two decades of experience in life sciences and capital markets, with a focus on scaling operations for healthcare companies [2] - The company is advancing innovative cancer therapies through AI-powered drug discovery, utilizing proprietary platforms [6][7] Company Overview - Rakovina Therapeutics is focused on developing innovative cancer treatments, particularly through DNA-damage response inhibitors [6][7] - The company aims to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners [7] Leadership Transition - Dr. Kideckel's appointment comes during a critical growth phase for the company, as stated by Executive Chairman Jeffrey Bacha [5] - David Hyman, the outgoing CFO, will remain in a consulting role after stepping down, having established robust financial systems for the company [5] Dr. Kideckel's Background - Dr. Kideckel has held leadership roles at ATB Capital Markets, Johnson & Johnson, and Alexion Pharmaceuticals, contributing to drug development and commercialization [3] - He holds a Ph.D. in Neuroscience and Statistics and an MBA from the University of Toronto [4]